Armis Biopharma® focuses on developing antimicrobial and anti-toxin products. Its technology includes a proprietary antimicrobial agent, Veriox®, that claims to eliminate various pathogens and chemical/biological threats.

Armis Biopharma®

Armis Biopharma | 45 followers on LinkedIn. Improving Societal Health by Protecting Humans, Animals, and the Environment from Harmful and Resistant Pathogens

Global Medical Device Executive ⇨ Strategic Direction, Vision & Execution for Transformative Product Innovation & Commercialization

Michael Voss

Operations Director - Product Development at Armis Biopharma

Jamie Reese

Manager at Armis Biopharma

Angela DeVary

Armis Biopharma

Another opportunity on Thursday to share the Armis Biopharma to investment opportunity.

May 31, 2023 - Armis Biopharma Announces 510(k) Clearance for VeriCyn® Wound Wash #pressrelease #VeriCynWoundWash #ArmisBiopharma

Our very own, Randy Hubbell will be presenting the Armis Biopharma opportunity at LSI on Thursday, March 21 at 8:45am PT (track 3). Also, you can visit both Randy Hubbell and Michael Voss at the Innovators Pavilion all week. #infectioncontrol #oralhygiene #decontamination #ArmisBiopharma #ArmisBiopharmaDental #LSI2024 #LSIalumni

On September 28, 2023 Armis Biopharma Announces Receipt of a $20.3 Million Contract with the Defense Threat Reduction Agency to Develop Veriox® DECON for Battlefield Wounds #Future #ArmisBiopharma #verioxdecon #dtra #defensethreatreductionagency #warfighter

Armis Biopharma Announces the Addition of Two Key Executives to Enhance Commercialization of their Product Portfolio. @RandyHubbell @MikeVoss @TedZiemann #Future #ArmisBiopharma #HumanResources #businessintelligence #Management

ARMI

COM:ARMISBIOPHARMA

Armis Biopharma®